Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I-II Study of PAXG in Stage III-IV Pancreatic Adenocarcinoma

Trial Profile

A Phase I-II Study of PAXG in Stage III-IV Pancreatic Adenocarcinoma

Phase of Trial: Phase I/II

Latest Information Update: 24 Aug 2018

At a glance

  • Drugs Capecitabine (Primary) ; Cisplatin (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PACT-19
  • Most Recent Events

    • 24 Aug 2018 Results of the phase II part of the trial (n=54) published in the European Journal of Cancer
    • 12 Sep 2017 Final results from the phase II part, presented at the 42nd European Society for Medical Oncology Congress.
    • 31 Aug 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top